Alexander Strasak

Roche (Switzerland) — Switzerland

Medicine · Health Sciences

42h-index5.9kcitations104works2.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Liver Disease Diagnosis and Treatment(17), HER2/EGFR in Cancer Research(15), Monoclonal and Polyclonal Antibodies Research(12), Folate and B Vitamins Research(8), Alcohol Consumption and Health Effects(8)

Publications102 total

Data from Association of γ-Glutamyltransferase and Risk of Cancer Incidence in Men: A Prospective Study
2023Open Access
Supplementary Table 1 from Prospective Study of the Association of Serum γ-Glutamyltransferase with Cervical Intraepithelial Neoplasia III and Invasive Cervical Cancer
2023Open Access
Data from Prospective Study of the Association of Serum γ-Glutamyltransferase with Cervical Intraepithelial Neoplasia III and Invasive Cervical Cancer
2023Open Access
Supplementary Table 1 from Association of γ-Glutamyltransferase and Risk of Cancer Incidence in Men: A Prospective Study
2023Open Access
Data from Association of γ-Glutamyltransferase and Risk of Cancer Incidence in Men: A Prospective Study
2023Open Access
Data from Prospective Study of the Association of Serum γ-Glutamyltransferase with Cervical Intraepithelial Neoplasia III and Invasive Cervical Cancer
2023Open Access
Supplementary Table 1 from Association of γ-Glutamyltransferase and Risk of Cancer Incidence in Men: A Prospective Study
2023Open Access
Supplementary Table 1 from Prospective Study of the Association of Serum γ-Glutamyltransferase with Cervical Intraepithelial Neoplasia III and Invasive Cervical Cancer
2023Open Access
Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer
Cancer Chemotherapy and Pharmacology·2019· 3 cited
Exposure–response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane
Cancer Chemotherapy and Pharmacology·2017· 28 cited
Population pharmacokinetics and exposure–response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2‐targeted regimens
British Journal of Clinical Pharmacology·2017· 19 citedOpen Access
Abstract P4-21-26: Population pharmacokinetics (PK) and exposure-response (E-R) analysis of trastuzumab emtansine (T-DM1) in patients with HER2+ metastatic breast cancer (MBC) who have received at least two prior regimens of HER2-directed therapy
Cancer Research·2017
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study
Journal of Clinical Oncology·2017· 408 citedOpen Access
A Phase I Pharmacokinetic Study of Trastuzumab Emtansine (T-DM1) in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function
Clinical Pharmacokinetics·2016· 13 cited
Ethnic sensitivity assessment of the antibody–drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer
Cancer Chemotherapy and Pharmacology·2016· 15 cited
Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study
Annals of Oncology·2016· 51 cited
The Use of Statistics in Medical Research: A Comparison of Wiener Klinische Wochenschrift andWiener Medizinische Wochenschrift
Austrian Journal of Statistics·2016· 3 citedOpen Access
Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer
Breast Cancer Research·2016· 47 citedOpen Access
Additional file 4: of Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer
Figshare·2016Open Access
An integrated pharmacokinetic-pharmacodynamic (PKPD) modeling analysis of trastuzumab emtansine (T-DM1)-induced thrombocytopenia (TCP) and hepatotoxicity in patients with HER2–positive metastatic breast cancer
2016· 3 cited
page 1 of 6Next →

Frequent Co-authors

Hanno Ulmer(15), Hans Concin(13), Karl Pfeiffer(12), Elfriede Ruttmann(10), Günter Diem(9), Kilian Rapp(8), Larry J. Brant(7), Jochen Klenk(6), Wolfgang Hilbe(6), Willi Oberaigner(6), Bernhard Glodny(5), Andreas Chemelli(5), Gabriele Nagel(4), Ruth M. Pfeiffer(4), Iris E. Chemelli-Steingruber(4), Monika Patre(3), Cecily Kelleher(3), Petra Innerhofer(3), Wegene Borena(3), Josef Klocker(3)